1. Pink Sheet
  2. >>Compliance

New Critical Medicines Alliance Says Join Us In Tackling Critical Medicines Shortages

 
• By Neena Brizmohun

Diversification of global supply chains, drug stockpiling, and boosting Europe's capacity to produce and innovate in the manufacturing of critical medicines and their ingredients are among the topics to be addressed by the European Commission’s forthcoming Critical Medicines Alliance.

Efforts are under way to prevent critical medicines shortages in the EU • Source: Shutterstock

Moves to set up a “Critical Medicines Alliance” in the EU to tackle the problem of critical medicines shortages by changing the way the bloc produces and procures drugs and reinforces its security of supply have stepped up a gear.

Drug companies, national authorities and many other pharmaceutical sector stakeholders have been invited to express their interest in joining the alliance, which will initially

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Distribution/Supply Chain

More from Compliance

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an audio interview.

US FDA Retirements Continue Unabated With Drug Inspectorate Leaders, Former Chief Counsel

 
• By Sue Sutter and Derrick Gingery

Alonza Cruse, director of the Office of Human and Animal Drugs Inspectorate, and two other senior inspection officials are departing, along with Mark Raza, chief counsel from 2021 until January.